Home

Health Care

Bernard Siegel of the Genetics Policy Institute Discusses Stem Cell Research

Bernard Siegel, executive director of the Genetics Policy Institute and co-chair of the World Stem Cell Summit, discusses the latest on NIH funding for embryonic stem cell research and tells us why he believes stem cell research is the future of medicine.

BIO India Shines the Global Spotlight on Biotech in India

The buzz at BIO India hones in on the lack of clarity and consistency within the clinical trials process

Contagion: How Would We Respond to a Pandemic?

Phyllis Arthur interviews Colonel Randall Larsen, CEO of the WMD Center, on the threat of a pandemic as portrayed in the movie Contagion which opens in theatres nationwide today.

Eva Jack, Chief Business Officer at Pulmatrix, on the Promise of Biotech

Jack discusses her greatest accomplishments, advice for industry leaders, and the promise of biotech. Pulmatrix is a clinical trial stage biotech company based in Lexington, Mass.

Dr. Steven Perrin, CEO, CSO and Vice Chairman, ALS Therapy Development Institute

What is ALS? How widespread is the disease? Are there any treatments for ALS? Dr. Steven Perrin discusses his organization's approach to stopping ALS.

When RARE is not so RARE!

Did you know that there is a community of sick and disabled women, children, and men that is so large that it outnumbers all of those with cancer and AIDS combined worldwide?

Capital Conundrum

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

2011 Dr. Paul Janssen Award winner Dr. Napoleone Ferrara

Dr. Napoleone Ferrara was named the 2011 winner of The Dr. Paul Janssen Award for Biomedical Research for his research on angiogenesis, the process of new blood vessel formation, and the isolation and cloning of vascular endothelial growth factor.

Ways Biotech Can Better Integrate Diverse Populations

Dr. Augustus White is author of “Seeing Patients: Unconscious Bias in Health Care” and a pioneer in equitable care. Dr. White will be delivering the keynote address at this year’s Diversity Summit at the 2011 BIO International Convention in Washington, D.C.

Rachel King, CEO of GlycoMimetics and a BIO Board member

GlycoMimetics’ Rachel King discusses the prevalence of sickle cell disease and urgency to find treatments.

Hervé Tettelin, Associate Professor in Microbiology and Immunology

Dr. Tettelin discusses his research in reverse vaccinology and as a pioneer of the pan-genome concept.

Melinda Moree, CEO of BIO Ventures for Global Health

Moree discusses the Forum and the importance of partnering to improving the health of people in developing countries.

Hillary Theakston, The Clearity Foundation

BIOtechNOW’s Tracy Cooley talks to Hillary Theakston, of The Clearity Foundation, is a non-profit organization dedicated to providing personalized treatment information to women with ovarian cancer.

Dr. John Reed on advancing Translational Services

BIOtechNOW’s Tracy Cooley talks to Dr. Reed from the   Sanford-Burnham Medical Institute about the NIH’s new National Center for Advancing Translational Sciences.

Recommendations for Novel Diagnostics Coverage and Reimbursement

Some of the most pressing challenges for the advent of personalized medicine relate to the reimbursement of novel diagnostics. Reimbursement policies must reflect the potential benefit that novel diagnostics can bring to patients and the healthcare system. This value proposition can be realized through reimbursement policy reforms that provide a clear and consistent pathway to obtain affirmative coverage, appropriate and timely coding, and market-based payment for diagnostic tests. BIO recommends that the following reforms be made to diagnostic reimbursement policy.

Letters, Testimony & Comments

PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the “Draft Guidance for Industry on Providing Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format .”
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the FDA Draft Plan on “Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making.”
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
BIO appreciates the opportunity to comment on the “WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology.” 
Immunogenicity: BIO Comments on Draft Guidance on Immunogenicity Assessment for Therapeutic Protein Products
April 12 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the “Draft Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products.”
Sunshine: BIO Files Comments on Estimated Burden of complying with Section 6002 of the Affordable Care Act (“the Sunshine Act”)
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with healthcare providers and we recognize the significant challenges that were presented in implementation of these ACA provisions. 
More Letters, Testimony & Comments →

Press Releases

Rx Open Activated to Report on Status of Pharmacies in Oklahoma
May 24 2013
Rx Response elevates to Alert status to address potential impact from Moore tornado on supply chain.
BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
BIO lauds the Senate for passing H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), yesterday by a unanimous vote.
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
Bill will accelerate R&D to help support nation’s preparedness against chemical, biological, radiological and nuclear threats.
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Pharmaceutical Research and Manufacturers of America PhRMA President and CEO John J. Castellani and BIO President and CEO Jim Greenwood released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V).
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
More Press Releases →